Tetra Bio-Pharma closes $10M public offering to fund drug research
CEO Guy Chamberland told OBJ earlier this year firm is working on breakthrough treatments for sepsis and acute respiratory distress syndrome.
Skip to content
Guy Chamberland
Ottawa drug-maker Tetra Bio-Pharma’s decade-long research effort may be poised to pay off
Product is designed to treat life-threatening conditions triggered when the body’s immune system “goes rogue” in response to infections such as COVID-19.
Ottawa’s Tetra Bio-Pharma graduates to TSX
Bioscience firm that’s developing cannabinoid-based treatments for chronic pain is slated to move up from TSX Venture Exchange on Aug. 4.
Shareholders approve Ottawa-based Tetra Bio-Pharma’s $12M acquisition
Tetra Bio-Pharma’s shareholders are endorsing the local firm’s plans to accelerate its cannabidiol research efforts as excitement around the market for hemp-based products heats up.
Orléans-based Tetra Bio-Pharma acquires cannabinoid research firm in $12M deal
An east-end Ottawa research firm has acquired another pharmaceutical company working in the cannabinoid space, bolstering both its product pipeline and roster of researchers. Tetra
Get our email newsletters
Get up-to-date news about the companies, people and issues that impact businesses in Ottawa and beyond.
By signing up you agree to our Terms of Use and Privacy Policy. You may unsubscribe at any time.
The Latest
Video
OBJ360
Sponsored
Sponsored
The Ottawa Hospital Foundation’s Campaign to Create Tomorrow
The $500-million fundraising campaign is the largest in our city’s history. It will reshape the future of healthcare in Ottawa and beyond.
